Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 262

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer